A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes.

ABSTRACT: Oral semaglutide (Rybelsus^®) is a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with 94% homology to human GLP-1. It is the first GLP-1RA developed for oral administration, and it comprises a co-formulation of the peptide semaglutide with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, which overcomes the challenges of peptide absorption in the acidic conditions of the stomach. Oral semaglutide is indicated for use as an add-on combination therapy (with other glucose-lowering agents, including insulin) or as a monotherapy (in patients who are intolerant to metformin) for type 2 diabetes when diet and exercise do not provide adequate glycemic control. In an extensive phase III clinical program including patients from across the disease spectr

SUBMITTER: Andersen A 

PROVIDER: S-EPMC8217049 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature